Rare Disease Research Challenges Explained
Rare Disease Research Challenges Explained
Publish Date: 2026-03-02 08:03:00
Source Domain: www.technologynetworks.com
The definition of a rare disease varies by location. In the United States, a condition affecting fewer than 1 in 200,000 people is considered rare, whereas in the European Union, this number is much lower at 1 in 2,000. However, one thing that remains consistent worldwide is inequitable access to treatment for people living with rare diseases (PLWRD).
This is driven by multiple factors, not least the unavailability of existing therapies. This often arises due to challenges throughout the drug development pipeline, from research to regulation. For example, the rarity of these diseases and the geographic distribution of patients complicates clinical trial development, and even when a drug makes it through trials and is approved for use, lack of funding often prevents patient access.
Worldwide, more than 400 million people live with rare diseases, which are often progressive and life-limiting in nature. This places considerable strain on PLWRD and their loved ones, as well as creating broader socioeconomic challenges.
Following a recent unanimous vote by the World Health Assembly to make rare diseases a global health priority, more must be done to address the unmet needs of PLWRD.
To learn more about the challenges faced in rare disease drug development and manufacturing, Technology Networks asked an array of experts the same question: “What would you consider to be the biggest challenge companies face when developing and manufacturing drugs for rare diseases?”
In parts two and three of this series, experts will cover the significance of treatment access for PLWRD and discuss opportunities to target existing inequities.
Annabella Amatulli, MSc, Head of Regulatory Affairs, Enterprise Therapeutics
“One of the biggest challenges, in my experience as a regulatory professional, is achieving global regulatory alignment. When developing a drug for a rare disease, patient populations are small. Ideally, you want to run a single,…
